(-0.13%) 5 462.12 points
(-0.32%) 38 987 points
(0.15%) 17 745 points
(0.42%) $81.17
(-3.48%) $2.66
(-0.83%) $2 311.50
(-0.20%) $28.81
(1.63%) $1 002.50
(0.28%) $0.936
(0.74%) $10.68
(0.39%) $0.791
(-0.21%) $87.31
Live Chart Being Loaded With Signals
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases...
Stats | |
---|---|
本日の出来高 | 246 |
平均出来高 | 7 396 |
時価総額 | 179 710 |
EPS | $-0.430 ( Q1 | 2024-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-26 | Van Der Baan Bastiaan Jeroen | Buy | 250 000 | Options to Purchase Common Stock |
2023-10-03 | Bernards Rene | Buy | 5 527 | Common Stock |
2023-10-02 | Bernards Rene | Buy | 4 473 | Common Stock |
2023-10-03 | Van Der Baan Bastiaan Jeroen | Buy | 10 000 | Common Stock |
2023-10-02 | Bernards Rene | Buy | 4 473 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 33 transactions |
Buy: 1 558 612 | Sell: 83 334 |
Lixte Biotechnology 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Lixte Biotechnology 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.66 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.66 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-39.85 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Lixte Biotechnology
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher\'s disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。